135046-48-9 Clopidogrel Hydrogen Sulfate
Contact : Mr.Thyen
Email us at firstname.lastname@example.org
Whatsapp : +86 180 3817 6818
Product Name: Clopidogrel hydrogen sulfate
Synonyms: PLAVIX;SR-25990C;CLOPIDOGREL BISULPHATE;CLOPIDOGREL HYDROGEN SULPHATE;CLOPIDOGREL SULPHATE;SR-25990C, Plavix, Methyl (+)-(S)-a-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate, Hydrogen sulfate salt;Methyl (S)-alpha-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulfate;SR-25990, Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate hydrogen sulfate
Product Categories: Active Pharmaceutical Ingredients;chiral;Intermediates & Fine Chemicals;Pharmaceuticals;Purinergics P2 receptor
Melting point : 184°C
Storage temp. : 2-8°C
Chemical Properties : White powders
Usage : Used as an antithrombotic .
Usage : Platelet aggregation inhibitors .
Anti-platelet aggregation drug
Thrombosis caused by arterial atheromatous plaque leads to acute thrombosis cardiovascular and cerebrovascular events. In this pathogenesis, platelets play a central role, which has been fully studied.
Clopidogrel hydrogen sulfate is similar to ticlopidine, which is a new anti-platelet aggregation drug, successfully developed by French Sanofi - Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation, such as recent onset of stroke, myocardial infarction and patients diagnosed with peripheral arterial disease. Many countries have already used it, including United States, Europe and China. This product inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation. Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment. Stop using 7 to 10 days, platelet function returned to normal state.
Clopidogrel is used to prevent heart attack and stroke in people who are at high risk of these events, including those with a history of myocardial infarction and other forms of acute coronary syndrome, stroke, and those with peripheral artery disease.
Treatment with clopidogrel or a related drug is recommended by theAmerican Heart Association and the American College of Cardiology for people.
Present for treatment with a myocardial infarction with ST-elevation including
A loading dose given in advance of percutaneous coronary intervention (PCI), followed by a full year of treatment for those receiving a vascular stent;
A loading dose given in advance of fibrinolytic therapy, continued for at least 14 days.
Present for treatment of a non-ST elevation myocardial infarction orunstable angina
Including a loading dose and maintenance therapy in those receiving PCI and unable to tolerate aspirin therapy.
Maintenance therapy for up to 12 months in those at medium to high risk for which a noninvasive treatment strategy is chosen;
In those with stable ischemic heart disease, treatment with clopidogrel is described as a "reasonable" option for monotherapy in those who cannot tolerate aspirin, as is treatment with clopidogrel in combination with aspirin in certain high risk patients.
It is also used, along with acetylsalicylic acid (ASA, aspirin), for the prevention of thrombosis after placement of a coronary stent or as an alternative antiplatelet drug for people intolerant to aspirin .